Drug Database
AL

alteplase (Reveliza / GNR004 / Revelise)

✓ Approved

Generium Pharmaceutical · PLAT · 重组蛋白

什么是 alteplase?

alteplase 是一种重组蛋白,由Generium Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名Reveliza, GNR004, Revelise
公司Generium Pharmaceutical
药物类别重组蛋白
分子靶点PLAT
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

alteplase 作用于 1 个分子靶点:

PLATplasminogen activator, tissue type (TPA, T-PA)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

alteplase 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersMyocardial infarction✓ Approved
Respiratory, thoracic and mediastinal disordersPulmonary thrombosis✓ Approved
Nervous system disordersDelayed ischaemic neurological deficit✓ Approved

相关研究文献

PubMedJournal of cerebrovascular and endovascular neurosurgery2026-11-17

Timing of transition from mechanical thrombectomy to intra-arterial alteplase and reperfusion quality in thrombectomy-refractory stroke.

Kim Kyeongsik K, Lee Su Ji SJ, Lee Joonwon J, Lee Hyungon H et al.

Mechanical thrombectomy (MT) is the standard treatment for acute ischemic stroke due to large vessel occlusion (LVO), but a subset of lesions remains refractory or technically challenging despite repeated mechanical attempts. Intra-arterial (IA) alteplase may be used as rescue therapy, but the optimal timing of transition from mechanical to pharmacological therapy remains unclear. We examined the association between the timing of this transition and reperfusion quality. We retrospectively reviewed 90 consecutive patients with LVO treated with MT between July 2021 and December 2022. Sixteen patients received rescue IA alteplase after ineffective or unfeasible MT. Procedure time was divided into an MT phase (femoral puncture to IA alteplase initiation) and an IA phase (IA alteplase initiation to the end of the procedure). The primary outcome was excellent reperfusion, defined as modified Thrombolysis in Cerebral Infarction (mTICI) 2c-3. Successful reperfusion (mTICI ≥2b) was achieved in 15 patients (93.8%), including excellent reperfusion in 8 (50.0%). The MT phase was shorter in the excellent than in the non-excellent reperfusion group (median, 49.5 vs. 87.5 minutes; p=0.028), whereas the difference in the IA phase was not statistically significant (36.5 vs. 75.5 minutes; p=0.068). No symptomatic intracerebral hemorrhage occurred. Good functional outcome (modified Rankin Scale ≤2) at 3 months was observed in 2 patients (12.5%). In this exploratory series, a shorter period of MT before transition to IA alteplase was associated with excellent reperfusion. This hypothesis-generating finding suggests that the timing of transition may matter and warrants evaluation in larger, controlled studies.

PMID 43040453
阅读全文 →
PubMedJournal of medical cases2026-11-17

Emergency Physician-Performed Point-of-Care Ultrasound Identified Left Atrial Myxoma in Acute Cerebellar Infarction.

Sato Takanobu T, Ichibayashi Ryo R, Sadamoto Sota S

Cardiac myxoma is a rare but potentially curable cause of cardioembolic stroke. Early identification of a potential cardiac embolic source may be challenging when neurological symptoms predominate during the initial emergency department evaluation. A 72-year-old woman presented to the emergency department with acute-onset dizziness and vomiting. Although her National Institutes of Health Stroke Scale score was 0, she was unable to walk independently. Electrocardiography demonstrated newly diagnosed atrial fibrillation. Because a cardioembolic mechanism was considered, the emergency physician performed bedside cardiac point-of-care ultrasound (POCUS), which revealed a highly mobile left atrial mass attached to the interatrial septum. POCUS was performed 28 min after arrival, before brain magnetic resonance imaging, which demonstrated multiple acute cerebellar infarctions without large-vessel occlusion. Intravenous alteplase was not administered despite presentation within the therapeutic time window. Anticoagulation with intravenous unfractionated heparin was initiated. Surgical resection was postponed after hemorrhagic transformation of the cerebellar infarction was detected on hospital day 14. The patient underwent complete tumor resection on hospital day 41, and histopathological examination confirmed cardiac myxoma. She was discharged on hospital day 54 with a favorable outcome. This case illustrates the potential value of emergency physician-performed cardiac POCUS for early identification of structural cardiac abnormalities during the initial evaluation of selected patients with suspected cardioembolic stroke.

PMID 43042193
阅读全文 →
PubMedInternational journal of molecular sciences2026-11-14

The Fibrinolytic System of the Chacma Baboon (Papio ursinus): Implications for Non-Human Primate Haemostatic Disease Models.

Joubert Jaco J, Meiring Muriel M, Janse Van Rensburg Walter W

Baboon models are useful for investigating haemostatic disorders and potential novel treatments. The fibrinolytic system is an integral component of these models and an important potential therapeutic target. We investigated the fibrinolytic system of the Chacma baboon (Papio ursinus), including the effects of sex and ABO blood group. Tissue-type plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), plasminogen, plasmin-α2-antiplasmin (PAP) complexes, thrombin activatable fibrinolysis inhibitor (TAFI), α2-antiplasmin, fibrinogen levels, and clot lysis times of 40 adult Chacma baboons were assessed. Plasminogen activation using escalating concentrations of streptokinase vs. alteplase was determined and compared with normal human plasma. The results were compared between O and non-O ABO blood groups, and between males and females. PAP complexes and fibrinogen were mostly within the human reference interval, while tPA, PAI-1 and α2-antiplasmin tended towards the lower limit. Plasminogen and TAFI were virtually undetectable with the human ELISA kits used. Alteplase was a potent plasminogen activator compared with streptokinase (p < 0.0001), resulting in brisker clot lysis in baboon than in human plasma (10.8 vs. 13.4 min). Blood group O baboons had higher fibrinogen levels (p = 0.0355), while males had lower fibrinogen (p = 0.0134) but higher PAP complex concentrations (p = 0.0188). Except for plasminogen and TAFI, the Chacma baboon fibrinolytic system appears broadly similar to its human counterpart. Streptokinase does not meaningfully activate Chacma baboon fibrinolysis, but alteplase elicits greater plasminogen activation than in humans. These findings, as well as sex- and ABO-blood-group-related differences in fibrinogen, should be considered when designing future pre-clinical drug testing experiments in this species.

PMID 43028192
阅读全文 →
PubMedDiagnostics (Basel, Switzerland)2026-11-14

Continuous Near-Infrared Spectroscopy as a Real-Time Monitor of Intravenous Thrombolysis in Acute Ischaemic Stroke: A Prospective Observational Emergency Department Study.

Şancı Emre E, Ercan Feride Fulya FF, Çıldır Hamza H, Bayram Başak B et al.

Background. Intravenous (IV) thrombolysis is the standard of care for acute ischaemic stroke (AIS), yet there is still no objective bedside tool for monitoring the brain continuously during the infusion. Near-infrared spectroscopy (NIRS) provides non-invasive, continuous measurement of regional cerebral oxygen saturation (rSO2). We evaluated whether bilateral frontal NIRS, and in particular the absolute interhemispheric difference in rSO2 (ΔNIRS), tracks the clinical trajectory of patients receiving IV alteplase in the emergency department (ED). Methods. A prospective observational cohort study was conducted in the ED of a tertiary university hospital. Consecutive adults receiving IV alteplase for AIS were screened, and those enrolled underwent continuous bilateral frontal NIRS monitoring. Bilateral rSO2, ΔNIRS, vital signs, Glasgow Coma Scale (GCS) and National Institutes of Health Stroke Scale (NIHSS) were recorded at baseline and at 0, 15, 30, 45, 60 and 120 min after the start of the infusion. Patients were classified by clinical trajectory during monitoring as improvement, no change, or deterioration. Results. Forty-one patients were analyzed (26 female, 63.4%; mean age 73.6 ± 14.8 years); 15 (36.6%) improved, 21 (51.2%) showed no change and 5 (12.2%) deteriorated. In the whole cohort, absolute rSO2 rose only slightly in the affected hemisphere and did not change in the unaffected hemisphere. However, affected-hemisphere rSO2 rose significantly in the improvement group (median 59 to 67; p = 0.001) and fell significantly in the deterioration group (p = 0.015). ΔNIRS narrowed from a median of 4 (IQR 3-9) at baseline to 1 (IQR 0-5) at 120 min in the improvement group (p = 0.034) and did not change significantly in the other groups. The two patients with acute complications desaturated bilaterally. NIHSS correlated strongly and inversely with GCS at every time point (ρ = -0.74 to -0.84; all p < 0.001). Conclusions. During IV thrombolysis in the ED, continuous bilateral frontal NIRS tracked the clinical trajectory. Because recanalisation and reperfusion were not assessed independently, what NIRS paralleled was the clinical course, not reperfusion itself. These hypothesis-generating findings warrant larger studies that validate ΔNIRS against perfusion or vascular imaging.

PMID 43028342
阅读全文 →
PubMedFrontiers in neurology2026-11-14

Lesion-directed quantitative EEG after reperfusion therapy is associated with malignant cerebral edema and functional outcomes in acute ischemic stroke: a prospective exploratory cohort study.

Wu Yu-Hsuan YH, Lin Chia-Yen CY, Huang Jin-An JA

Ischemic stroke causes electrophysiological slowing within minutes which may precede detectable structural changes, making electroencephalography (EEG) a sensitive bedside marker of tissue at risk. Prior quantitative EEG (qEEG) studies often averaged bilateral or frontal activity, focused on thrombectomy, and were recorded at 24 h. We tested whether a lesion-directed alpha-to-delta ratio (lesion-ADR) within 72 h after reperfusion is associated with malignant cerebral edema (MCE) and functional outcomes. In a prospective single-center cohort of anterior-circulation ischemic stroke treated with intravenous alteplase (IV-rtPA), endovascular thrombectomy (EVT), or both, a 7-min EEG was obtained ≤72 h after reperfusion. Lesion-ADR was defined as the mean ADR of ipsilesional electrodes; the reperfusion-to-EEG interval (ΔT) was recorded. The primary outcome was MCE (midline shift ≥5 mm and/or decompressive hemicraniectomy). Secondary outcomes were favorable functional outcomes at discharge and 90 days (modified Rankin Scale [mRS] 0-2). Model discrimination was assessed using ROC analysis and AUC with bootstrap internal validation. Adjusted associations were assessed using parsimonious Firth penalized logistic regression models. Forty-nine patients were included. For MCE, the combined lesion-ADR + ΔT model achieved an apparent AUC of 0.888 (95% CI 0.765-0.960); bootstrap internal validation yielded an optimism-corrected AUC of 0.889. For discharge independence (mRS ≤ 2; n = 9), the ADR-only model showed an apparent AUC of 0.899. Lesion-ADR remained associated with favorable outcome after separate adjustment for admission NIHSS (OR 1.438 per 0.1-unit increase; p = 0.009) and reperfusion treatment modality (OR 1.367; p = 0.022). For 90-day independence (n = 13), the ADR-only AUC was 0.759 (95% CI 0.615-0.869) and the ADR-only model showed moderate discrimination for 90-day functional independence. The association with 90-day outcome was attenuated after accounting for admission NIHSS (OR 1.245 per 0.1-unit increase; p = 0.088). A brief lesion-directed ADR obtained within 72 h after reperfusion was associated with functional outcomes, while its combination with EEG timing showed encouraging discrimination for MCE in this cohort. These exploratory findings suggest lesion-directed qEEG may serve as a potential adjunctive biomarker after reperfusion therapy and warrant validation in larger cohorts.

PMID 43031565
阅读全文 →
PubMedFrontiers in neurology2026-11-12

Implementation of tenecteplase for acute ischemic stroke: workflow and safety in routine care including off-label use.

Sekita Alexander A, Macha Kosmas K, Borutta Matthias C MC, Sprügel Maximilian I MI et al.

Tenecteplase is increasingly adopted as an alternative to alteplase for intravenous thrombolysis in acute ischemic stroke. However, real-world data describing complete institutional transitions, particularly in extended treatment windows and off-label clinical scenarios, remain limited. We conducted a retrospective cohort study of consecutive patients treated with intravenous thrombolysis during the 12 months before and after a complete institutional transition from alteplase to tenecteplase (June 2023-May 2025). Primary endpoints were in-hospital workflow metrics (door-to-needle, door-to-imaging, imaging-to-needle, door-to-groin, and door-to-recanalization times). Safety outcomes included any intracranial hemorrhage and symptomatic intracranial hemorrhage according to the SITS-MOST definition. Outcomes were analyzed in the overall cohort, in patients treated beyond 4.5 h after symptom onset, and in patients receiving oral anticoagulation. Multivariable-adjusted and propensity score-based analyses, including augmented inverse probability of treatment weighting, were applied to account for baseline differences. Among 591 thrombolyzed patients (rt-PA n = 278; TNK n = 313), 31% were treated beyond 4.5 h and 14% under oral anticoagulation. Tenecteplase was associated with significantly shorter door-to-needle times (31 vs. 35 min; p = 0.004), primarily driven by reduced imaging-to-needle intervals (13 vs. 16 min; p = 0.004). Door-to-groin times were numerically shorter with tenecteplase but did not differ significantly (70 vs. 76 min; p = 0.07). Rates of any intracranial hemorrhage (8% vs. 7%; p = 0.61) and symptomatic intracranial hemorrhage (3% vs. 1%; p = 0.34) were comparable. Similar safety findings were observed in patients treated beyond 4.5 h after symptom onset and in those receiving oral anticoagulation, with consistent results across multivariable-adjusted and propensity score-based analyses. Institutional transition to tenecteplase was associated with improved in-hospital workflow without evidence of increased hemorrhagic complications. These findings support the feasibility of implementing tenecteplase as the standard thrombolytic agent in routine comprehensive stroke center practice, including in extended treatment windows and selected off-label clinical scenarios.

PMID 43016687
阅读全文 →

注册免费账户还可查看另外 3720 篇文献

免费注册查看全部文献 →

了解更多alteplase